The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Hepatorenal Syndrome: A historical appraisal of its origins and conceptual evolution
Kidney Int. 2021 Mar 26;S0085-2538(21)00290-8. doi: 10.1016/j.kint.2021.02.037.Online ahead of print.
Garabed Eknoyan1, Murray Epstein2
Author information
1The Selzman Institute of Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, TX. Electronic address: geknoyan@bcm.edu.
2Division of Nephrology and Hypertension, University of Miami Miller School
Abstract
The hepatorenal syndrome (HRS), a progressive but potentially reversible deterioration of kidney function constitutes a serious complication of hepatic decompensation. Coexistence of liver/kidney damage, mentioned in the dropsy literature, was highlighted by Richard Bright in 1827 and confirmed in 1840 by his contemporary nephrology pioneer Pierre Rayer. Cholemic nephrosis was described in 1861 by Friedrich Frerichs, and the renal tubular lesions of HRS by Austin Flint in 1863. The term 'acute hepato-nephritis' was introduced in 1916 by Paul Merklen and its chronic form designated HRS by Marcel Dérot in 1930s. HRS then was applied to renal failure in biliary tract surgery and to cases of coexistent renal and hepatic failure of diverse etiology. The pathogenesis of HRS was elucidated during the 1950 studies of renal physiology. Notably, studies of salt retention in edema and its relation to regulating the circulating plasma volume by John Peters and subsequently Otto Gauer that defined the concept of "effective blood volume" and the consequent elucidation of ascites formation in liver failure. Parallel studies of intrarenal hemodynamics demonstrated severe renal vasoconstriction and preferential cortical ischemia to account for the functional renal dysfunction of HRS. Dialysis and liver or combined liver-kidney transplantation transformed the fatal HRS of old into a treatable disorder by the 1970s. Elucidation of the pathogenetic mechanisms of renal injury and refinements in definition, classification and diagnosis of HRS since then have allowed for earlier therapeutic intervention with combined intravenous albumin and vasoconstrictor therapy enabling the continued improvement of patient outcomes.